公司概述
INmune Bio Inc. operates as a clinical-stage immunology company dedicated to developing pharmaceutical agents designed to reprogram the patient's innate immune system for the treatment of various diseases within the United States. The enterprise functions within the healthcare sector, specifically classified under the biotechnology industry, which typically involves high research and development expenditures and significant regulatory risks before product commercialization. The company's current scale is reflected in a market capitalization of $34.03 million, an annual revenue of $50,000, and a workforce consisting of 21 employees. These financial figures indicate that the organization is in an early-stage development phase where revenue generation is minimal relative to its market valuation, a common characteristic for biotechnology firms focused on advancing product candidates for hematologic malignancies, solid tumors, and chronic inflammation.
财务健康
The company reported a trailing twelve-month revenue of $50,000 alongside a net income of -$45,933,000 and an EBITDA of -$30,785,000. The substantial disparity between the negligible revenue and the significant net loss highlights a cost structure dominated by operating expenses, likely driven by research, development, and general administrative costs inherent in the clinical-stage biotechnology model. Free cash flow stands at -$13,025,125, indicating that the company is currently burning cash, which limits its immediate financial flexibility to fund operations without external capital raising or asset monetization. Margin analysis reveals a gross margin of 100.0%, suggesting that direct costs of goods sold are negligible at this stage, contrasted by an operating margin of -61738.0% and a profit margin of 0.0%, which reflect the intense operational leverage and lack of profitability typical of pre-revenue entities. The balance sheet shows cash reserves of $24.75 million against total debt of $1.03 million, resulting in a debt-to-equity ratio of 4.40, suggesting a leveraged position relative to equity but with significant liquidity coverage for short-term obligations. The current ratio is 3.55, which indicates a robust short-term liquidity position where current assets are more than three times current liabilities. Return on equity is recorded at -165.2% and return on assets at -53.7%, metrics that reveal management's current inability to generate positive returns on the capital invested, a standard but risky profile for companies in deep clinical development phases.
估值评估
Valuation multiples for INmune Bio Inc. present a challenging picture with a P/E ratio (TTM) listed as N/A due to lack of earnings, while the forward P/E is calculated at -1.64. The divergence between a non-existent trailing earnings multiple and a negative forward multiple implies that the market is pricing the stock based on future potential rather than historical profitability, often seen in speculative biotechnology assets. The price-to-book ratio is 1.45, indicating that the market values the company at a 45% premium over its net asset book value, which may reflect expectations of future asset appreciation or intangible value not captured on the balance sheet. Alternative valuation metrics show a price-to-sales ratio of 680.58 and an EV/EBITDA of -0.34, suggesting that the stock is priced extremely high relative to its tiny sales base and negative earnings power. The 52-week price range spans from a low of $1.09 to a high of $11.64, meaning the stock price is currently positioned between these extremes with significant volatility. The beta value of 0.89 suggests that the stock's price volatility is slightly lower than the broader market, moving with a sensitivity of 0.89 times the market index.
Growth & Income
The available data indicates that revenue growth year-over-year and earnings growth year-over-year are both N/A, precluding a direct comparison of earnings growth rates against revenue growth in the traditional sense. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the firm retains all earnings and cash flows to reinvest into research and development efforts rather than distributing income to shareholders. The absence of dividend payments aligns with the growth profile of a clinical-stage company that prioritizes capital allocation toward advancing its pipeline of product candidates for hematologic malignancies, solid tumors, and chronic inflammation. Consequently, the overall growth and income profile is characterized by zero current income generation and reliance on external financing to sustain operations until potential product approvals or commercialization milestones are achieved.